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Abstract The study presents an assessment of mechanism of
action and a pilot clinical study of efficacy and safety of the
Er:YAG laser for the treatment of stress urinary incontinence
(SUI). The subject of this study is a treatment of SUI with a
2940 nm Er:YAG laser, operating in a special SMOOTH
mode designed to increase temperature of the vaginal mucosa
up to maximally 60–65 °C without ablating the epidermis.
Numerical modelling of the temperature distribution within
mucosa tissue following an irradiation with the SMOOTH
mode Er:YAG laser was performed in order to determine the
appropriate range of laser parameters. The laser treatment pa-
rameters were further confirmed by measuring in vivo tem-
peratures of the vaginal mucosa using a thermal camera. To
investigate the clinical efficacy and safety of the SMOOTH
mode Er:YAG laser SUI treatment, a pilot clinical study was
performed. The study recruited 31 female patients suffering
from SUI. Follow-ups were scheduled at 1, 2, and 6 months
post treatment. ICIQ-UI questionnaires were collected as a
primary trial endpoint. Secondary endpoints included
perineometry and residual urine volume measurements at
baseline and all follow-ups. Thermal camera measurements
have shown the optimal increase in temperature of the vaginal
mucosa following treatment of SUI with a SMOOTH mode
Er:YAG laser. Primary endpoint, the change in ICIQ-UI score,
showed clinically relevant and statistically significant im-
provement after all follow-ups compared to baseline scores.
There was also improvement in the secondary endpoints. Only
mild and transient adverse events and no serious adverse
events were reported. The results indicate that non-ablative
Er:YAG laser therapy is a promising minimally invasive
non-surgical option for treating women with SUI symptoms.
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Introduction
Female stress urinary incontinence [1] is a significant public
health problem, with estimated prevalence rates ranging from
4–35 % of adult women [2].
The initial treatment option for SUI is pelvic floor muscle
training (PFMT), which produces good results, but often fails
to achieve consistent long-term improvement because of poor
patient compliance and lack of support and guidance [3, 4].
Traditional surgical approaches such as open or laparoscopic
colposuspension and anterior vaginal repair have been largely
replaced with less-invasive midurethral sling suspension pro-
cedures, which have popularized the surgical option of
treating SUI among patients [5, 6]. While midurethral sling
procedures are highly effective, they are associated with ad-
verse events and complications such as bleeding, bladder per-
foration, urethral injury, infection, and groin pain [7]. In recent
years, single incision polypropylene mesh mini-slings have
been introduced and have become very popular due to the
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minimal invasiveness of the procedure. However, they
have since been associated with frequent side effects,
prompting the FDA in 2012 to require extensive post-
market studies for all marketed mini-slings [8]. This has
resulted in increased caution among patients considering
SUI surgery and in a search for new, safer procedures
among physicians and the industry.
It is well known that using laser energy to achieve heat
pulsing (i.e., temporarily increasing the temperature) of colla-
gen can improve collagen structure and initiate neo-
collagenesis [9, 10]. As a result of the temperature increase,
intermolecular cross-links that stabilize collagen triple-helix
structure are broken, which leads to the shrinkage of collagen
fibrils and improvement in tissue firmness.
Collagen is an important component of pelvic floor
supportive structures—it makes up more than 80 % of
protein content of the endopelvic fascia. Childbirth trau-
ma can lead to destruction of collagen fibers in the
pelvic floor, while aging slows down the synthesis of
new collagen, both resulting in decreasing collagen con-
tent [11]. It was shown that pubocervical fasciae of
incontinent women have a low collagen content [12]
and also that stress urinary incontinence is more fre-
quent in women with reduced collagen content in their
anterior vaginal walls [13].
The above facts support the idea that laser-mediated heat
pulsing of the endopelvic fascia and pelvic floor tissue could
represent an effective non-surgical method for treating female
urinary incontinence and other disorders resulting from dimin-
ished pelvic floor support.
One existing treatment for SUI that most resembles the
mechanism of action of laser therapy is the treatment of SUI
using radiofrequency (RF) emitting devices. Although RF
methods are less invasive than surgery, transurethral treatment
comes with a need for anesthesia and increased risk of post-
operative pain and urinary tract infections [14–17].
Here, we investigate a novel, minimally invasive al-
ternative SUI therapy that is based on thermally induc-
ing reinforcement of the pelvic floor using an infra-red
Er:YAG laser. The Er:YAG laser wavelength of
2.94 mm is strongly absorbed in water which is the
major constituent of human soft tissue. A precisely con-
trolled sequence(s) of sub-ablative Er:YAG laser pulses
are delivered to the intravaginal mucous tissue in order
to achieve controlled heating of the collagen in the
deeper mucosa layers, without over-heating of the mu-
cosa surface.
The aim of the present study was to assess the efficacy of
the new laser treatment in achieving the optimal rise in the
temperature of the anterior vaginal wall that supports the ure-
thra and to assess the clinical outcome of this new non-




Fotona Dynamis laser manufactured by Fotona d.d., Slovenia,
incorporating an Er:YAG laser with enabled SMOOTH mode
was used in this study. The BSMOOTH mode pulse^ with a
duration of 250 msec consisted of a fast sequence of six indi-
vidual SP mode (300 μsec) micro pulses with intra-pulse tem-
poral separation of 50 msec. Full beam handpiece R11 and
patterned (pixelated) handpiece PS03 together with the gyne-
cological adapters (G-set) were used to deliver Er:YAG laser
energy onto the vaginal mucous tissue. The Fotona handpiece
PS03 is equipped with a pixel screen, resulting in the overall
laser spot having a patterned (dotted) internal beam structure,
with the centers of individual circular beam dots of diameter
of 0.85 mm being separated by approximately 2 mm. The
motivation behind the design of the patterned handpiece
PS03 is to make the treatment less invasive by reducing the
treatment area to isolated beam islands.
Numerical model
In this study, we use a previously developed numerical model
[18], to determine the influence of laser parameters on the
desired treatment end effects in the treated tissue. The numer-
ical model consists of three main stages: laser energy absorp-
tion, heat diffusion deeper into the tissue, and heat convection
into the surrounding air. The thermodynamic behavior of tis-
sue water, which is the major absorber of Er:YAG (2.94 μm)
laser irradiation, is combined with the elastic response of the
surrounding solid medium. The tissue is treated as a two com-
ponent medium, consisting of microscopic spherical cavities
where water is trapped in a non-absorbing elastic medium.
Heat absorption is modeled by taking into account nonlinear
water absorption coefficient, which is decreased by deposited
energy laser irradiation [19].
The boundaries of the tissue are on the top side of cylindri-
cal computational domain subjected to convection [20]. Other
edges of computational domain are thermally insulated using
Neumann boundary condition, which prevents the heat to be
lost through the edges.
The diffusion of heat is introduced into the model using
three-dimensional unsteady heat conduction equation in cy-
lindrical coordinates with heat-source term
q
: ¼ 1−μrð ÞμaI
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where μr is the coefficient of reflection at tissue surface, μa the
absorption coefficient, I the depth distribution of intensity of
incident laser beam, T the tissue temperature, λ the thermal
conductivity of the tissue, ρ the density, and c the specific heat
modified by the nonlinear model of Majaron et al. [18]. The
same parameters were used in this study.
Thermal camera measurements to assess heating
of the mucosal tissue
Thermal camera (ThermaCAM P45, Flir, USA) measure-
ments were made of the mucosa surface temperatures follow-
ing irradiation of the introitus area with the Fotona Dynamis
Er:YAG Laser System. Measurements were made following
irradiation of the introitus with the R11 (full-beam, used in the
first two steps of the Incontilase® procedure (see below BPilot
clinical study^ for protocol details) and PS03 (patterned
handpiece, used in the third step of the Incontilase® proce-
dure) handpieces. Both handpieces were set to a 7 mm overall
spot size, and the SMOOTH mode pulse was selected with a
fluence of 3, 6, and 10 J/cm2 (resulting in micro pulse fluences
of 0.5, 1, and 1.67 J/cm2, respectively). Up to four consecutive
SMOOTH pulses were applied to the vaginal mucosa at the
repetition rate of 1.6 Hz.
No alteration to the commercial laser device was made.
The laser was fired as in a normal operation by pressing the
footswitch, and the camera image was recorded following an
emitted laser pulse. Measurement accuracy as according to the
camera manufacturer was ±2 °C.
Since the camera software assumes a uniform body tem-
perature, the measured temperatures represent a weighted av-
erage of the mucosa temperature within the penetration depth
of the detected thermal radiation of approximately 50 μm.
Pilot clinical study
This pilot study included 31 patients suffering from stress
urinary incontinence.
The inclusion criteria for recruitment to the study were
history of vaginal delivery, stress urinary incontinence, normal
cell cytology, negative urine culture, no injuries and bleeding
in the vaginal canal, introitus and vestibule.
The exclusion criteria were severe prolapse and damage of
the recto-vaginal fascia, patients with urge incontinence, pa-
tients with severe neurological conditions associated with in-
continence (multiple sclerosis, spinal cord injury, stroke,
Parkinson’s disease), neurogenic bladder, insulin-dependent
diabetes mellitus, actual urinary tract infection, hematuria,
age ≤18 and >70 years, pregnancy, less than 24 weeks after
vaginal delivery, body mass index (BMI) >30, intake of pho-
tosensitive drugs, injury or/and active infection in the treat-
ment area, and undiagnosed vaginal bleeding.
The study was approved by the Ethics committee of the
University of Rijeka School of Medicine in Rijeka, Croatia,
and was carried out in Ob/Gyn Menopause Clinic in Zagreb,
Croatia.
The procedure was performed with a 2940 nm Er:YAG
laser (XS Dynamis, Fotona, Slovenia), using a special modal-
ity, SMOOTH mode, which delivers laser energy in a non-
ablative, thermal-only manner, based on the pulsing sequence
designed to achieve deep heating of the vaginal mucosa to
around 60 °C. Protocol was done according to manufacturer’s
instructions (Incontilase® application notes, Fotona). The pa-
tients were placed in lithotomy position, and laser probes,
consisting of a specially designed speculum and a laser deliv-
ery handpiece were introduced into the vaginal canal. Briefly,
the protocol consisted of three consecutive steps, during
which the laser irradiation was applied to anterior vaginal wall
(PS03 patterned beam, four consecutive SMOOTH pulses
with a fluence of 10 J/cm2), the whole circumference of vag-
inal canal (R11 full beam, four consecutive SMOOTH mode
pulses with a fluence of 3 J/cm2), and vestibule area (PS03
patterned beam, four consecutive SMOOTH mode pulses
with a fluence of 3 J/cm2), respectively. Several passes of laser
energy were applied to each area. On average, cumulative
energy applied in all three steps reached from 2500–3000 J,
depending on the length of the vaginal canal. The average
treatment duration was approximately 10min. Patient discom-
fort, treatment tolerability, and potential adverse events were
monitored during laser treatment. No anesthesia was used be-
fore or during the session. Patients were instructed to avoid
increased intra-abdominal pressure and refrain from sexual
intercourse for 14 days after intervention. First follow-up ap-
pointments were scheduled at 1 month, the second follow-up
at 2 months, and the third follow-up at 6 months after the
intervention.
The degree of incontinence and its impact on quality of life
(QoL) were assessed with the International Consultation on
Incontinence Questionnaire-Urinary Incontinence Short Form
(ICIQ-UI SF) [22], where a maximum score of 21 represents
permanent incontinence. The questionnaire allows for the as-
sessment of the prevalence, frequency, and perceived cause of
urinary incontinence and its impact on everyday life. The re-
sults of the ICIQ-UI SFmay be divided into the following four
severity categories: mild (1–5), moderate (6–12), severe (13–
18), and very severe (19–21) [22]. The residual urine volume
was measured at each follow-up immediately after the patient
returned from the washroom. Measurements were performed
with a DC-8 ultrasound unit (Mindray, China). For the mea-
surement of muscle strength of the pelvic diaphragm, an
Apimedis perineometer (EXTT-101, Korea) was used to de-
termine maximal and average pressure (mmHg) and mean
duration of contractions (seconds).
Level of statistical significance was set to p<0.05 and all
confidence intervals were given at 95 % level. In all instances,
Lasers Med Sci (2016) 31:635–643 637
two-tailed tests of statistical significance were used. The ab-
solute and relative differences between medians at baseline
and at second follow-up measurement were given. Statistical
significance of the difference between mean outcomes values
at baseline and at follow-up measurements was done by one-
way ANOVAwith Dunn’s multiple comparison tests. To com-
pensate for high loss to follow-up, a last observation carried
forward (LOCF) sensitivity analysis was done The assump-
tion of the LOCF is that the patients lost to follow-up
remained at the same level measured at their last appointment
(either baseline or previous follow-up).
All statistical analyses were performed using GraphPad
Prism statistical software.
Results
Numerical modelling of thermal penetration depth
Numerical modelling was carried out for laser parameters and
conditions as used during thermal camera measurements. The
calculations confirmed that no tissue ablation occurs at the
Incontilase® laser treatment parameters. In order to compare
predictions of the theoretical model with thermal camera mea-
surements, Fig. 1a shows calculated average temperatures of a
50-μm thick superficial tissue layer, 20 msec following laser
irradiation. It is clear that spatially local temperature accumu-
lation after exposure to full-beam handpiece R11 is markedly
higher than after exposure to the patterned handpiece PS03.
Figure 1b shows calculated normalized tissue temperature
distributions in the longitudinal direction, for the patterned
handpiece, and a SMOOTH mode pulse fluence of 10 J/cm2,
as a function of the number of SMOOTH mode pulses deliv-
ered sequentially at a repetition rate of 1.6 Hz.
As can be seen, Bheat pumping^, i.e., sequential irradiation
of tissue with appropriately temporally separated laser pulses
results in a temperature distribution several hundred microns
deep within the tissue, without overheating of the surface
temperature.
Thermal camera measurements to assess heating
of the mucosal tissue and thermal penetration depth
calculation
Figure 2a shows the measured temporal evolution of the tissue
temperature during an irradiation with a sequence of four
SMOOTH mode pulses. From the graph, the temporary heat
accumulation can be observed as an overall increase of tem-
perature after each SMOOTH mode pulse.
Figure 2b shows the measured tissue surface temperature,
as a function of the number of consecutively delivered
SMOOTHmode pulses, as obtained with the PS03 handpiece,
for SMOOTH mode pulse fluences of 3, 6, and 10 J/cm2, and
with the R11 handpiece for a fluence of 3 J/cm2. In agreement
with the theoretical model, for the same delivered laser
fluence, the patterned beam handpiece results in a lower local
temperature increase than the full beam handpiece.
Pilot clinical study
Total of 31 womenwere included into the study. Their mean age
was 46.6 years with themean bodymass index of 23.2 (Table 1).
All patients (100 %) have completed the first follow-up. At 2nd
follow-up, 2 months after the intervention, 17 (56.7 %) patients
remained in the study and 14 (43.3%) were lost to follow-up. At
the third follow up, 6 months after intervention, 14 (43.3 %)
patients remained in the study, while 17 (56.7 %) were lost to
follow-up. Baseline age, parity, average birth weight, and body
mass index of those who have remained in the study at later
follow-ups were similar to those at the baseline. It appears that
later lost to follow-up has not been associated with baseline
values of any of the outcomes (Table 1).
No serious adverse events were observed or reported
throughout the course of laser treatment and the follow-up
period. All patients experienced sensation of warmth or
Fig 1 a Calculated temperature on the tissue surface following laser
treatment with the PS03 handpiece for two different SMOOTH mode
fluences (6 and 10 J/cm2) and with the R11 handpiece (fluence = 3 J/
cm2), as a function of the number of consecutively delivered SMOOTH
mode pulses. b Calculated normalized temperature change distribution in
relation to depth below tissue surface following laser irradiation as a
function of the number of consecutively delivered SMOOTH mode
Er:YAG pulses using the handpiece PS03 at a SMOOTH mode pulse
fluence of 10 J/cm2
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teasing during treatment. Most patients reported in-
creased vaginal discharge in the next few days after
the procedure and slight vulvar edema, which disap-
peared within 48 h after the treatment. The Visual
Analogue Scale (VAS, 0–10) pain level of 2 was
reported by 5 % of participants, while 95 % had
score 0.
The ICIQ-UI score, which was the primary efficacy end-
point of the study, was significantly decreased in all follow-
ups compared to baseline. The score was decreased on average
by 6.3 points after 1month, by 5.3 points after 2months, and by
5.1 points 6 months after treatment (Fig. 3 and Table 2). At
baseline, all participants had urinary incontinence; 3/31
(9.7 %) had mild, 11/31 (35.5 %) moderate, 13/31
(41.9 %) severe, and 4/31 (12.9 %) suffered from very
severe urinary incontinence. At the first follow-up,
1 month after the intervention, number of those with
ICIQ-UI score = 0 indicating no urinary incontinence in-
creased to 10/31 (32.52 %) (Table 2).
The LOCF sensitivity analysis has revealed statistically
significant and clinically relevant differences after the inter-
vention (Table 3).
There was a statistically significant decrease in post void
residual urine volume at all the first two follow-ups compared
to baseline measurement (Table 2).
Perineometry measurements have shown a trend of im-
provement, but not statistically significant compared to base-
line (Table 2).
Fig. 2 a An example of the measured temperature development on the
introitus mucous tissue during four consecutively delivered SMOOTH
mode Er:YAG (Fotona Dynamis XS) laser pulses (PS03 handpiece,
SMOOTH mode pulse fluence: 3 J/cm2, total fluence delivered: 4 × 3 J/
cm2 = 12 J/cm2). b Measured temperature on the introitus mucosa
following laser treatment with the PS03 handpiece for two different
SMOOTH mode fluences (6 and 10 J/cm2) and with the R11 handpiece
(fluence = 3 J/cm2), as a function of the number of consecutively
delivered SMOOTH mode pulses
Table 1 All patients’
characteristics at the baseline and
baseline characteristics of those
who remained into the study at the









Age 46.8 ± 9.1 46.8 ± 9.1 46.4 ± 9 46.7 ± 7.2
Parity 2 (1.7–3) 2 (1.7–3) 2 (2–3) 2 (1–3)
Average birth weight (kg) 3.5 ± 0.5 3.5 ± 0.5 3.5 ± 0.6 3.5 ± 0.5
BMI 23.3 ± 2.7 23.3 ± 2.7 23.8 ± 3.2 24.14 ± 3
BMI, n (%)
Normal (≤24.9) 23 (74.2) 23 (74.2) 10 (58.8) 8 (57.1)
Overweight (25.0–29.9) 8 (25.8) 8 (25.8) 7 (41.2) 6 (42.9)
Obese (≥30.0) 0 0 0 0
Total 31 (100) 31 (100) 17 (100) 14 (100)
ICIQ-UI 12.9 ± 5 12.9 ± 5 12.5 ± 4.7 14± 3.7
Residual urine 3.8 (1.1–10.5) 3.8 (1.1–10.5) 3 (1.9–9.9) 5.6 (1.4–13)
Perineometry
Maximal (mmHg) 9 (7.5–11.9) 9 (7.5–11.9) 9.7 (7.6–12.2) 8.4 (7.6–12.1)
Average (mmHg) 4.6 (3.8–6.4) 4.6 (3.8–6.4) 5.2 (3.9–6.7) 4.6 (4–6.2)
Duration (seconds) 10.7 (5.6–23.9) 10.7 (5.6–23.9) 10 (6.1–21.7) 10.4 (6.1–21.7)
Data are presented as medians (intra-quartile range), means ± SD, depending on the normality of the data, or n
(%), where patient distributions were calculated
BMI body mass index (body weight in kg divided by body height in m2 )
Lasers Med Sci (2016) 31:635–643 639
However, the LOCF analysis of both post void residual
volume and perineometry measurements showed significant
improvement after treatment (Table 3).
Discussion
Our theoretical calculations and in vivo thermal camera mea-
surements have demonstrated that treatment with the
SMOOTH mode Er:YAG laser at Incontilase® laser parame-
ters results in a non-ablative temperature increase which is
within the temperature window required to achieve collagen
contraction and to initiate neocollagenesis in the vaginal mu-
cosa in vivo. Published data shows that the shortening of the
collagen fibrils without irreversible denaturation of their struc-
ture requires that temperatures do not exceed the optimal tem-
perature range of 60 to 70 °C [23]. Both, numerical modelling
and in vivo thermal camera imaging show that the
Incontilase® treatment parameters result in the temperature
increase of vaginal wall mucosa up to approximately 65 °C.
Therefore, the Incontilase® treatment increases the mucosa
temperature up to the optimal temperature range, but does
not exceed the temperature threshold for surface ablation or
irreversible denaturation of collagen.
The Er:YAG laser radiation acts almost like a surface heater
due to the extremely shallow optical penetration depth of itsmid-
infrared wavelength and relies on heat diffusion to affect deeper
layers of the mucosa. Since at sub-ablative fluences (F<2 J/cm2)
of a single Er:YAG pulse the thermally affected layer is below
10 μm, the laser procedure described in this study (Incontilase®)
utilizes repetitive stacking of sub-ablative Er:YAG laser pulses,
which can result in a tenfold increase in the depth of thermally
affected soft tissue [24]. The concept of non-ablative pulse stack-
ing of Er:YAG laser pulses has been already successfully applied
in other medical areas, such as dermatology [25, 26].
We have used numerical modelling to calculate the spatial
and temporal temperature distribution within the tissue during
and after exposure to four SMOOTH mode pulses (as used in
the Incontilase® method).
Repetitive SMOOTH pulsing resulted in heat deposition
and temperature rise that reached several hundred microns
below tissue surface (Figs. 1 and 2). These results are in agree-
ment with those by Majaron et al. [18], whose numerical cal-
culations predict deep tissue heating and resulting coagulation
depths of above 100 μm for the irradiation of soft tissue with a
train of Er:YAG pulses with parameters comparable to those
of the procedure used in this study (SMOOTH mode).
Our calculations are also supported by histologic investi-
gations using an in vivo rat skin model from Majaron et al.
[27], which have confirmed prior theoretical predictions by
demonstrating that a train of 3–10 Er:YAG pulses, delivered
at 10–33 Hz repetition rate, and with the total full beam deliv-
ered fluence of up to 10 J/cm2, could achieve non-ablative
coagulation of collagen deeper than 200 μm below the
epidermal-dermal junction.
Fig. 3 Mean scores from the ICIQ-UI questionnaire, which was the
primary effectiveness endpoint, at baseline, and at 1, 2, and 6 months
after treatment. Circles represent all patients that have participated in
the measurement at each follow-up. * comparison test—***p < 0.001;
**p< 0.01; *p < 0.05
Table 2 Differences from baseline before the intervention, at 1st, 2nd, and 6th month follow-up
Baseline (n= 31) 1-month follow-up (n= 31) 2-month follow-up (n= 17) 6-month follow-up (n= 14)
P value AD P value AD P value AD
ICIQ-UI 12.9 ± 5 6.6 ± 6.1*** <0.001 −6.3 7.6 ± 6.7** 0.005 −5.3 7.8 ± 5.7* 0.01 −5.1
Residual urine 3.8 (1.1–10.5) 0.6 (0.1–3.3)* 0.01 −3.2 0.4 (0.2–3.7)* 0.04 −3.4 1.0 (0.2–3.3) 0.07 −2.8
Perineometry
Maximal (mmHg) 9 (7.5–11.9) 11 (8.5–16.4) 0.36 2 12.2 (9.9–24.8) 0.06 3.2 11.5 (9.7–21) 0.18 2.5
Average (mmHg) 4.6 (3.8–6.4) 6 (4.7–9.5) 0.12 1.4 6 (4.5–15.2) 0.16 1.4 5.7 (4.5–14.7) 0.18 1.1
Duration (seconds) 10.7 (5.6–23.9) 15.4 (9.3–28.9) 0.75 4.7 29 (11.2–32.7) 0.15 18.3 27 (10.5–46) 0.09 16.3
Data are presented as mean ± SD or medians (interquartile ranges), depending on the normality of the data
P P value (one-way ANOVA, multiple comparison; or Kruskal-Wallis test, depending on the normality of the datasets), AD absolute difference in
medians at baseline and follow-up, * indicates statistical significance
***p< 0.001; **p< 0.01; *p < 0.05
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Further, histological data from a clinical study of Er:YAG
eyelid treatment byDrnovsek-Olup et al. [26] that used similar
laser parameters (Fotona SMOOTH mode, full beam, cumu-
lative fluence 2 J/cm2) as are used in the present study, has
shown deep (200 μm) collagen denaturation and skin regen-
eration without ablation of epidermis.
The rationale for using the patterned handpiece PS03
comes from fractional photothermolysis, the relatively new
method of skin rejuvenation [28, 29]. Unlike standard full
beam treatments, where the whole of the selected target area
is irradiated, fractional photothermolysis seeks to only affect
certain zones within the selected target area, producing tiny
dot- or pixel-like treated areas in the skin. This leaves the other
zones within the skin perfectly intact; hence, only causing
fractional effect through the heat of the light source. The skin
heals much faster than if the whole area was treated, as the
‘healthy’ untreated tissue surrounding the treated zones helps
to fill in the affected area with new cells.
As the numerical model and thermal camera measurements
have demonstrated, at the same fluence, treatment with the full
beam handpiece R11 results in a higher local vaginal tissue
temperature increase in comparison to treatment with the pat-
terned handpiece PS03. This is because when the patterned
PS03 handpiece is used, the heat diffuses both longitudinally
into the deeper tissue layers, and transversally into the un-
irradiated volume between the pixels. Because of this higher
thermal diffusion in the transverse direction, the local temper-
ature achieved after irradiation with PS03 handpiece at 10 J/
cm2 is nearly the same as the one after irradiation with the full
beam R11 handpiece at 3 J/cm2.
In order to show that the new approach in treating SUI is
effective and safe, a pilot clinical trial of Incontilase® SUI
treatment was performed.
The treatment resulted in clinically meaningful and statis-
tically significant improvement in the SUI symptoms accord-
ing to the primary efficacy endpoint—the ICIQ-UI
questionnaire. The improvement was first observed at the first
follow-up, 1 month after the treatment, and has remained sta-
ble to the third follow-up, 6 months after treatment. ICIQ-SF
score at all follow-ups was improved bymore than five points.
Recently, a minimum important difference in the ICIQ-SF,
indicating a clinically meaningful improvement, was deter-
mined to be 2.5 points [30]. The improvement of ICIQ-UI
score was strongest at the first follow-up and slightly smaller
at each subsequent follow-up. Although the clinically mean-
ingful effect was endured, it might be beneficial to repeat the
treatment at least once in order to fortify the effect.
There was significant decrease in the residual urine volume
after treatment; the effect remained strong at all follow-ups,
indicating improved voiding efficiency following treatment.
Perineometry measurements included maximum pressure,
average pressure, and pressure duration of pelvic floor muscle
contraction. All parameters showed a trend of increase, which
was not statistically significant. These results were somewhat
expected, as the increases in perineometry measurements in-
dicate some increased support to pelvic floor muscles, which
is not dramatic, since the laser therapy does not directly act on
pelvic floor muscles. It would be interesting to combine laser
therapy with PFMT and evaluate the effect of the combined
non-invasive treatments, as simultaneous muscle exercise
combined with laser reinforcement of the connective tissue
could bring synergistic benefits to pelvic floor reinforcement.
The treatment was proven to be safe—all of the observed
side effects (most frequent were edema and stronger vaginal
discharge) were mild and of transient nature. The Er:YAG
laser SUI treatment as described in the present study is mini-
mally invasive—the laser thermal energy in the form of
SMOOTH pulse sequences is delivered intra-vaginally, with
the emphasis on the anterior vaginal wall, which supports the
bladder and urethra that lie above. There is no need for anes-
thesia, since only moderate increase of temperature is
achieved without any surface ablation. Because the
Table 3 Sensitivity analysis. Differences from baseline before the intervention, at 1st, 2nd, and 6th month follow-up under the assumption that the 2nd
and 6th months follow-up values for all those that were lost for follow-up were the same as at last measured follow-up
Baseline (n= 31) 1-month follow-up (n= 31) 2-month follow-up (n= 31) 6-month follow-up (n = 31)
P value AD P value AD P value AD
ICIQ-UI 12.9 ± 5 6.6 ± 6.1*** <0.001 −6.3 6.9 ± 6.3*** <0.001 −5.3 7 ± 6*** <0.001 −5.9
Residual urine 3.8 (1.1–10.5) 0.6 (0.1–3.3)* 0.02 −3.2 0.8 (0.25–3.6)* 0.03 −3.4 1.0 (0.2–3.5)** 0.007 −2.8
Perineometry
Maximal (mmHg) 9 (7.5–11.9) 11 (8.5–16.4) 0.19 2 11.5 (10.1–20.2)* 0.02 2.5 12 (9.7–40)* 0.02 3
Average (mmHg) 4.6 (3.8–6.4) 6 (4.7–9.5) 0.06 1.4 6.1 (4.6–11.9)* 0.02 1.5 5.8 (4.5–12.4)* 0.03 1.2
Duration (seconds) 10.7 (5.6–23.9) 15.4 (9.3–28.9) 0.4 4.7 18.5 (9.5–29.8) 0.2 7.8 16.2 (10.5–36.2) 0.09 5.5
Data are presented as mean ± SD or medians (interquartile ranges), depending on the normality of the data
P one-way ANOVA, Dunn’s multiple comparison test, statistical significance between baseline and follow-up, AD absolute difference in medians
between baseline and follow up, * indicates statistical significance
***p< 0.001; **p< 0.01; *p < 0.05
Lasers Med Sci (2016) 31:635–643 641
SMOOTH pulse sequences are pre-programmed to achieve
the abovementioned moderate temperature rise, there is min-
imal risk of over-heating and thermal damage to the tissue.
Since laser treatment of stress urinary incontinence is a
novel method, there were only a few pilot studies published
on the use of laser for this indication, all showing promising
results [31, 32]. Gaspar et al. [33] used a fractional CO2 laser
for strengthening and tightening the vaginal mucosa and have
measured a significant improvement in the same perineometry
measurements that were done in the present study. While the
indication was not the same, the mechanism of action of laser
treatment for SUI is largely due to thickening and strengthen-
ing of the vaginal wall, with an emphasis to the anterior wall,
which supports the bladder and urethra. Besides laser treat-
ment, patients from the Gaspar et al. study also received
intravaginally applied platelet-rich plasma and pelvic floor
muscle exercise with biofeedback control, which explains
the stronger perineometry effects and gives further arguments
for future trials of combined effects of laser and PMFT.
We recognize that the main limitations of the pilot study are
the lack of a control group, high loss to follow-up, and the
relatively short follow-up time. However, the study was de-
signed as an exploratory pilot study and the presented results
are promising as well as extremely useful in design of future,
larger randomized control trials. High loss to follow-up is most
likely due to the lack of incentive and geographical dispersion
of the patients. It is interesting to note that at the first follow-up,
which was completed by all patients, there was a marked im-
provement in the severity scale, showing that almost a third of
patients scored 0, meaning no incontinence. Of these, 50 %
were lost to both subsequent follow-ups, three completed only
the 2-month follow-up, where the score remained 0, but then
missed the 6-month follow-up. Two out of 10 patients that have
scored 0 at the 1-month follow-up completed both 2 and 6-
month follow-ups—both remained completely dry, with the
score of 0. This indicates that patients with completely im-
proved results might have lost incentive to further participate
in the study, since there were no predicted incentives or mech-
anisms to keep patients enrolled throughout.
The differences in baseline values between responders and
those that were lost to follow-up were quite small. In order to
check the impact of the missing data on the results, sensitivity
analysis was done, where last measured observation was car-
ried forward to the subsequent missed follow-ups. All of the
methods yielded comparable, clinically meaningful and statis-
tically significant results of the primary effectiveness end-
point. The results were even better in the sensitivity analysis,
once more confirming that the lost-to-follow-up patients were
largely the ones with very much improved results at the first
follow-up.
We conclude that the non-ablative SMOOTH mode
Er:YAG intravaginal laser treatment induces deep thermal ef-
fect on the vaginal wall, which based on our pilot study seems
to result in a clinically meaningful improvement of female
SUI. The SMOOTH mode Er:YAG laser therapy is a promis-
ing minimally invasive, safe, and effective option for treating
women with SUI symptoms. Randomized control trials are
needed for further evaluation of this new SUI treatment.
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